PeptideInfo
العربيةGet the app
☰
GLP-1 & MetabolicHuman RCTApproved (US)

Tirzepatide

Mounjaro · Zepbound

Tirzepatide co-activates the receptors for GLP-1 and GIP. GIP-receptor activity supports insulin sensitivity, while GLP-1-receptor activity strengthens appetite suppression. Combined incretin signaling also contributes to fat oxidation and energy expenditure beyond the effects of GLP-1 signaling alone.

Not medical advice. Educational reference only.

Typical dose
2.5, 5, 7.5 or 15 mg subcutaneously once weekly
Route
Subcutaneous injection
Storage
Refrigerate the mixed solution at 2–8 °C; use within 28 days.

What is Tirzepatide?

Tirzepatide is Eli Lilly’s dual agonist of GIP and GLP-1 receptors and was the first approved twincretin therapy. Mounjaro is the diabetes presentation; Zepbound is the obesity presentation. In SURMOUNT-1, 15 mg over 72 weeks produced average weight reductions reaching 22.5%, placing it at the highest efficacy level among approved obesity drugs at its approval. An additional approval for obstructive sleep apnea followed in 2024. SURMOUNT-2 studied adults with obesity and type 2 diabetes.

Mechanism of action

Tirzepatide co-activates the receptors for GLP-1 and GIP. GIP-receptor activity supports insulin sensitivity, while GLP-1-receptor activity strengthens appetite suppression. Combined incretin signaling also contributes to fat oxidation and energy expenditure beyond the effects of GLP-1 signaling alone.

Targets: GLP-1 receptor (GLP1R) · GIP receptor (GIPR)

Research indications

  • Weight Loss

    Most effective

    The randomized SURMOUNT-2 study evaluates weight management in people who have both obesity and type 2 diabetes.

    Human, randomised1 reference

  • Blood Sugar Control

    Most effective

    Metabolic research evaluates improved glucose regulation and lower A1C in type 2 diabetes.

  • Cardiovascular Health

    Effective

    Cardiovascular investigation concerns the potential to reduce events in people at high risk.

  • Metabolic Syndrome

    Effective

    Research considers improvements across several features of metabolic syndrome together.

Research protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalAmountFrequencyRoute
Starting Dose (Week 1–4)2.5 mgOnce weeklySubcutaneous injection
Escalation (Week 5–8)5 mgOnce weeklySubcutaneous injection
Intermediate dosing during weeks 9–127.5 mgOnce weeklySubcutaneous injection
Maximum Dose15 mgOnce weeklySubcutaneous injection

Interactions

  • Other GLP-1 Agonists (e.g. Semaglutide + Tirzepatide)

    Avoid

  • Insulin

    Monitor

  • Sulfonylureas

    Monitor

  • Metformin

    Compatible

  • SGLT2 Inhibitors

    Compatible

  • Oral Contraceptives

    Caution

  • Warfarin / Blood Thinners

    Monitor

  • NAD+

    Compatible

How to reconstitute and inject

Diluent: Use only bacteriostatic water; avoid saline because precipitation can occur.

  1. Let your refrigerated Tirzepatide vial stand for 15–20 minutes so it reaches room temperature before mixing.
  2. Disinfect the rubber stopper using an alcohol swab. Wait for all of the alcohol to air-dry.
  3. Measure the calculated bacteriostatic water volume with a sterile syringe. Use BAC water only; saline can lead to precipitation.
  4. Deliver the water slowly against the vial’s inner wall. Keep the stream from striking the powder directly.
  5. Mix by gently rotating the vial in circles. Avoid vigorous shaking, which can break down the peptide.
  6. Wait 2–3 minutes until dissolution is complete. Inspect the liquid for a clear appearance without color.
  7. Measure your calculated dose in an insulin syringe for administration beneath the skin.
  8. Choose your abdomen, upper arm or thigh for subcutaneous administration. Change sites between injections to help prevent lipodystrophy.
  9. Keep the mixed vial at 2–8 °C in the refrigerator. Use the solution within 28 days of preparation.

What to expect

Week 1–2
Appetite may begin to diminish. Early adjustment can include mild nausea or a feeling of fullness.
Week 2–4
Smaller portions and fewer cravings may become noticeable, along with early changes in weight.
Week 4–8
More pronounced appetite control and steady weight reduction may coincide with improved glucose levels where relevant.
Week 8–16
Larger reductions in weight and improved energy may occur as metabolic measurements begin to change.
Week 16–24
Later expectations include major weight-loss milestones, cardiovascular benefits and a more favorable lipid profile.
Week 24+
The anticipated later phase includes the largest effect and sustained, broader metabolic improvements; this is not an individual outcome guarantee.

Side effects and safety

  • Nausea that is generally short-lived and related to dose · Most common
  • Constipation or diarrhea as doses increase
  • Vomiting, particularly during initiation or after a dose increase
  • Less appetite and an earlier feeling of fullness
  • Bruising or redness around the injection area
  • Tiredness, particularly during the initial weeks
  • Pancreatitis; stop use at once if severe abdominal pain occurs · Rare
  • Effects involving thyroid C cells · Rare

Contraindications

  • Avoid use if you have MEN2 or a previous thyroid cancer diagnosis.

Tirzepatide: approved in the US.

Regulatory status

  • US

    Approved

    FDA — prescription tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound for obesity, with an obstructive sleep apnea indication added in 2024. Telehealth prescribing is available.

    Rx required
    Yes
    Telehealth
    Available

Frequently asked questions

How does weight loss compare with semaglutide?

Average weight reductions can be greater with tirzepatide, but individual responses vary. SURMOUNT-1 reported up to 22.5% with 15 mg tirzepatide; STEP 1 reported approximately 14.9% with 2.4 mg semaglutide. These are separate trials. A clinician should consider goals, insurance coverage and cost.

Which side effects have been reported?

Reported gastrointestinal effects include nausea at 18%, diarrhea at 16%, vomiting at 8% and constipation at 11%; injection reactions occur around 3%. Escalation over 20 weeks helps limit these effects. Pancreatitis, gallbladder disease and thyroid effects are rare concerns. Percentages here lack a specified dose or population.

How are Mounjaro and Zepbound different?

Both contain tirzepatide at 2.5–15 mg. Mounjaro treats type 2 diabetes; Zepbound covers chronic weight management at BMI ≥30, or ≥27 with a comorbidity. Formulary placement, insurance coverage and dosing kits differ. Zepbound also has the 2024 obstructive sleep apnea indication.

References

  1. Tirzepatide Once Weekly for the Treatment of Obesity. (2022)

    PMID 35658024DOI 10.1056/NEJMoa2206038

  2. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. (2021)

    PMID 34170647DOI 10.1056/NEJMoa2107519

  3. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). (2024)

    PMID 38252888DOI 10.1210/clinem/dgae038

  4. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. (2023)

    PMID 37385275DOI 10.1016/S0140-6736(23)01200-X

  5. Tirzepatide for Obesity Treatment and Diabetes Prevention. (2025)

    PMID 39536238DOI 10.1056/NEJMoa2410819

  6. MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information (2022)

  7. Tirzepatide obesity studies on ClinicalTrials.gov (2024)

  8. ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information (2023)